CORDIS
EU research results

CORDIS

English EN
Advanced affinity tools and technologies for high throughput studies of the human proteome

Advanced affinity tools and technologies for high throughput studies of the human proteome

Objective

High specificity affinity reagents (‘binders’) are essential probes for proteome research, enabling the detection and localisation of multiple proteins in tissues and fluids in health and disease, through the application of binder-based technologies (affinity proteomics). This proposal links the high throughput production of quality-controlled, recombinant binding molecules of different types (antibody fragments, engineered scaffolds, aptamers) with advanced applications (capture microarrays, multidimensional fluorescence imaging, single molecule detection, intracellular knockdown) in the analysis of human proteome targets. The partners are five established SMEs and five leading academic groups, each with a reputation for innovation, engaged in binder production and characterisation or protein detection technologies. The project will aim to resolve bottlenecks in high throughput binder production and application technologies, including cost, throughput, automation and quality. The linkage of production, quality control and applications will be exemplified by targeting kinases and other proteins involved in the TGF-beta and MAP kinase signal transduction pathways, implicated in many diseases and where the availability of high quality binding reagents is particularly needed and drug development is actively evolving. As well as potential products, it will provide the SMEs with opportunities to exemplify and improve their technologies for future exploitation in proteomics, diagnostics and therapeutics.

Coordinator

BABRAHAM BIOSCIENCE TECHNOLOGIES LIMITED

Address

Babraham Hall
Cb22 3at Cambridge

United Kingdom

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 392 575

Administrative Contact

Rebecca Paxton (Ms.)

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

BIAFFIN GMBH & CO KG

Germany

EU Contribution

€ 389 000,40

Source Bioscience plc

United Kingdom

EU Contribution

€ 177 000

MOLECULINK AB

Sweden

EU Contribution

€ 487 600

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Germany

EU Contribution

€ 313 560

TECHNISCHE UNIVERSITAET BRAUNSCHWEIG

Germany

EU Contribution

€ 370 880

UNIVERSITAET KASSEL

Germany

EU Contribution

€ 234 657,60

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 158 772

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 311 000

SOMALOGIC INC

United States

EU Contribution

€ 153 000

Project information

Grant agreement ID: 222635

Status

Closed project

  • Start date

    1 March 2009

  • End date

    29 February 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 4 059 348,40

  • EU contribution

    € 2 988 045

Coordinated by:

BABRAHAM BIOSCIENCE TECHNOLOGIES LIMITED

United Kingdom